Last Transcript: Avadel Pharmaceuticals plc

1 day+0.05%
Current year+0.42%
Current year 21.4
Extreme 21.395
21.76
1 year 14.31
Extreme 14.31
23.57
3 years 6.38
Extreme 6.38
23.57
5 years 6.38
Extreme 6.38
23.57
10 years 6.38
Extreme 6.38
23.57
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 07/12/2020
Chief Tech/Sci/R&D Officer - 02/12/2019
Investor Relations Contact - -
Date Insider Type Main position Quantity % Market Cap. Importance
2/13/26 A
Weiss Asset Management LP
SellCompany 11,112,052 11.3600%
2/12/26 A Issuer sale

Director

468,962 0.4794%
2/12/26 A Issuer sale

Chairman

407,984 0.4171%
Change 5-day change 1-year change 3-year change Capi.($)
+0.05%-.--% - - 2.12B
+0.43%+6.59%+53.41%+103.85% 1,120B
+0.90%-2.25%+33.02%+62.23% 616B
+0.71%+3.24%+25.81%+93.86% 504B
-0.13%+5.98%+32.91%+50.39% 367B
+0.52%+0.24%+73.92%+40.15% 360B
-0.95%+4.70%+19.51%+43.00% 288B
-1.98%+3.73%-0.86%+13.43% 258B
-0.35%+4.25%+46.21%+50.76% 234B
-0.75%+3.32%+32.53%+97.21% 194B
Average -0.15%+3.61%+35.16%+61.65% 437.88B
Weighted average by Cap. +0.13%+3.83%+39.18%+71.44%
Logo Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a biopharmaceutical company. The Company's product, LUMRYZ, is an extended-release formulation of sodium oxybate, indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy. Its approach includes applying solutions to the development of medications that address the challenges patients face with treatment options. Its drug delivery technologies include MICROPUMP, LIQUITIME, and MEDUSA. Its MICROPUMP technology allows for the development of modified-release solid, oral dosage formulations of drugs. Its LIQUITIME technology allows for the development of modified-release oral products in a liquid suspension formulation, which may make such formulations particularly suited for children and/or patients having issues swallowing tablets or capsules. Its MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs.
Employees
188
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
MarketScreener Ratings - Avadel Pharmaceuticals plc
  1. Stock Market
  2. Stocks
  3. AVDL Stock